Novavax, Inc. is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.
The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus. In addition to its COVID-19 vaccine, Novavax is advancing candidates targeting respiratory syncytial virus (RSV) and seasonal influenza. These programs leverage the same nanoparticle and adjuvant technologies to address ongoing unmet needs in respiratory infectious disease.
Novavax operates globally, with research and development facilities in North America and manufacturing partnerships in Europe, Asia and Africa. Collaborations with organizations such as the Serum Institute of India and SK bioscience support its ability to supply vaccines in diverse markets. This international footprint enables the company to respond rapidly to public health emergencies and to pursue broad distribution of its products.
Under the leadership of President and Chief Executive Officer John C. Jacobs, who joined the company in 2021, Novavax has focused on scaling manufacturing capacity and securing regulatory approvals for its vaccine candidates. The company’s executive team and board include experienced professionals from the vaccine and biopharmaceutical industries, guiding its efforts to expand the global reach of its proprietary vaccine platform.